Article

APA House Call: Treating Trauma Patients During the COVID-19 Pandemic

Author(s):

It might be particularly difficult for psychiatrists to treat trauma patients through telehealth means.

The 2020 American Psychiatric Association (APA) Annual Meeting was cancelled this year, with plans made to convert the world-leading psychiatry conference into a two-part virtual session and educational platform for attendees.

In lieu of regular on-site coverage, HCPLive® will be running a series of interviews, insights, and reporting on topics that frequently headline the APA meeting—featuring familiar experts.

As the coronavirus disease 2019 (COVID-19) pandemic forces virtually the entire world into social isolation, the medical field has taken to telehealth as a reasonable way to maintain non-urgent care without increasing the risk of infection.

Psychiatry might be 1 of the fields leading this charge, as many practices have already implemented some telehealth into their services.

However, some conditions may be more difficult than others to treat under these new circumstances.

In an interview with HCPLive®, David H. Jiang, MD, an assistant professor of psychiatry at Mount Sinai Morningside, explained how trauma might be particularly difficult to treat in the age of social isolation because the sense of trust is a major part of healing for trauma patients and they are often unable to regain that sense of comfort from telehealth appointments.

With that said, Jiang said psychiatrists must find a way to reach their patients and help them through this troubling time

Jiang also discussed how nurses and doctors may be more at risk for developing signs of trauma due to the unsustainable level of strain the COVID-19 virus is putting on the healthcare system and how prevalent feelings of disassociation may be for trauma patients.

Related Videos
Shawn Kwatra, MD: Making the Connection Between Prurigo Nodularis, Atopic Dermatitis, and Itch
Will Herrington, MBBS, MD, MA: Empagliflozin Follow-up Data Informs Clinical Care for CKD
Jennifer Lai Yee, MD, PhD, MPH: Honing in on Sparsentan’s Benefit in Genetic FSGS
Highlighting Recent Therapies for Dermatologists, with James Del Rosso, DO
Ladan Zand, MD: Obinutuzumab Promising Option for Refractory, Primary FSGS
Rahul N. Khurana, MD: Phase 1 Results on Vamikibart for Uveitic Macular Edema | Image Credit: Northern California Retina Vitreous Associates
Sunir J. Garg, MD: | Image Credit: Wills Eye Hospital
James Del Rosso, DO: Discussing What’s New in the Medicine Chest for Dermatologists
What to Look Forward To at the Fall Clinical Dermatology Conference, with Raj Chovatiya, MD, PhD
© 2024 MJH Life Sciences

All rights reserved.